NEWS
Switch Therapeutics appoints David M. Holtzman, M.D. to its Scientific Advisory Board and announces its first development candidate, CASi-APOE, a liver-sparing APOE RNAi therapy
Biotech expert and renowned Alzheimer’s disease researcher, David M. Holtzman, M.D., joins Switch’s Scientific Advisory Board to support advancement of company’s novel neurodegenerative pipeline…
Switch Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprietary CASi (Conditionally Activated siRNA) platform…
In the News: Eight biotech companies advancing in the field of siRNA
Small interfering RNA (siRNA) carries great promise in the biotechnology industry. As an essential component of the RNA interference (RNAi) pathway…
Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference…
Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer
Veteran RNA expert, oligonucleotide chemist and biotech industry expert, Charles Allerson, Ph.D., joins Switch Therapeutics from DTx Pharma to lead the acceleration of the Company’s novel CASi platform —
Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.